RADIESSE Injectable Implant
FDA premarket approval P050037/S110 · decided 2021-08-27
Approval details
- PMA number
- P050037
- Supplement
- S110
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- RADIESSE Injectable Implant
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Merz North America, Inc.
- Date received
- 2020-11-20
- Decision date
- 2021-08-27
- Days to decision
- 280 days
- Decision code
- APPR
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Franksville, WI
- Statement
- Approval for modification of the Calcium Hydroxylapatite (CaHA) particle manufacturing process to allow for an Alternate Processing Pathway (APP) to process CaHA particle byproducts.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| DESCRIBE PFD Patch (K172689) | Merz North America, Inc. | 2017-11-29 |